Ishares Msci Spain ETF vs BIO-TECHNE Corp — how do they compare? Ishares Msci Spain ETF trades at $57.83 (market cap $2.36B), while BIO-TECHNE Corp trades at $72.46 (market cap $11.37B). The key difference: BIO-TECHNE Corp is far larger — about 4.8× Ishares Msci Spain ETF's market cap, and BIO-TECHNE Corp pays a 0.44% dividend while Ishares Msci Spain ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold Ishares Msci Spain ETF for 40 Days and BIO-TECHNE Corp for 63 Days on average.
| EWP | TECH | |
|---|---|---|
Market Cap | $2.36B | $11.37B |
Volume | 297,635 | 3,153,511 |
Sector | Broad Market / Factor | Health |
52-Week High | $63.23 | $72.61 |
52-Week Low | $48.33 | $43.31 |
Typical Hold Time | 40 Days | 63 Days |
Enterprise Value | — | $11.40B |
Dividend Yield | — | 0.44% |
Signals from Pluang's Aura AI — not financial advice
EWP, the iShares MSCI Spain ETF, trades at $57.82, down 1.73% on the day amid a bearish technical signal. The ETF offers concentrated exposure to Spanish equities with a discounted 16x P/E and 2.7% yield, heavily weighted in financials and utilities. Recent ECB rate hikes to 2.5% and energy-driven inflation pressures create macroeconomic headwinds for European markets.
While EWP provides attractive valuation and yield, the bearish technical outlook and ECB tightening cycle present near-term challenges. The concentrated portfolio in Spanish banks and utilities offers stability but limits diversification. Upside potential depends on Spain's economic resilience amid broader eurozone pressures.
TECH trades at $72.53, near its 52-week high of $72.70, with a bullish technical signal and strong institutional interest. Recent earnings show mixed results, beating in Q2 2026 but missing in Q1. The company maintains solid profitability with a 65.77% gross margin, though net income declined to $73.40M in 2025. Shareholders approved an acquisition by Merck KGaA at $73.00 per share, a key near-term catalyst.
Outlook is positive due to the pending acquisition, but risks include execution challenges and valuation concerns with a high P/E of 62.53. Analyst consensus is divided with 46% buy ratings, suggesting cautious optimism. The stock offers limited upside to the acquisition price, making it suitable for event-driven investors.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Latest headlines on both assets
EWP is a country-specific ETF that tracks the performance of the Spanish equity market. It provides targeted access to large and mid-sized companies in Spain, with heavy weightings in financials and utilities like Banco Santander and Iberdrola.
Read more on EWP →Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. The company reports in two segments, protein sciences (75% of revenue), and diagnostics and genomics (25%). The protein-focused segment makes equipment and associated consumables for protein characterization and analysis and sells antibodies for research and clinical purposes. In diagnostics, Bio-Techne provides controls and calibrators for diagnostic manufacturers and has a portfolio of diagnostic oncology assays. The United States accounts for about 55% of revenue, and the firm also has operations in EMEA (20% of sales), the U.K. (5%), and APAC (15%), with the rest of the world accounting for the remaining 5%.
Read more on TECH →